USBC INC

Company Overview

USBC Inc (operating as Know Labs in the latest filings) is a Technology company in the Scientific & Technical Instruments industry developing a Bio‑RFID radio/microwave spectroscopy platform aimed at non‑invasive sensing (notably glucose monitoring) and related industrial use cases. Management has pivoted toward monetizing intellectual property through a Know Labs Technology Licensing (KTL) program and pursuing industrial applications to avoid costly human trials, while still advancing clinical validation/FDA pathways for medical uses. Recent quarters show materially lower operating losses driven by deep cuts to R&D, SG&A and stock‑based compensation, but cash is critically low (~$0.17M at 6/30/2025) with significant short‑term convertible debt and contingent financings (e.g., Goldeneye SPA) determining near‑term runway. The company also faced NYSE American compliance actions, a 1‑for‑40 reverse split and trading suspension/reinstatement earlier in 2025, all of which have governance and funding implications.

Executive Compensation Practices

Executives historically had a significant equity component in pay (stock‑based compensation) typical for early‑stage instrument/medtech developers; the filing shows management materially reduced equity grants and other variable spend to preserve cash. Going forward, pay is likely to emphasize milestone‑ and event‑driven incentives (FDA/clinical milestones, licensing revenue milestones, successful financings/closing conditions) and may rely more on deferred or security‑based arrangements (preferred shares, warrants, convertible instruments) given the strained liquidity. The small headcount and heavy use of consultants mean fewer broad employee equity pools and more concentrated executive/founder ownership, increasing the importance of retention awards tied to commercialization or licensing achievements. Convertible debt and recent conversions to Series H preferred can alter insider economics and dilute common equity, so incentive design may favor instruments that protect investor/funder interests while aligning management to capital‑raising and IP‑monetization milestones.

Insider Trading Considerations

Because the company is small‑cap with very low liquidity and a thin float, insider transactions can move the stock and convey substantial information about funding and regulatory outlook; watch Form 4 filings closely for purchases, exercises, sales, and conversions. Insider activity is likely to cluster around material corporate events—financing closings (Goldeneye SPA, bridge loans, ATM financings), debt conversions to preferred, reverse split and NYSE compliance milestones, and FDA/clinical updates—each of which could be material nonpublic information subject to blackout periods and heightened legal risk. Expect use of settlement mechanisms (preferred shares, warrants, convertible notes) and possible 10b5‑1 plans to manage trading; also monitor related‑party transactions and debt exchanges that can mask economic transfers. Given the sector’s regulatory sensitivity, trades made shortly before or after clinical/regulatory disclosures deserve extra scrutiny from researchers and traders.